A. Ardern-Jones

发表

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study

Ali Amin Al Olama, T. Sellers, D. Schaid, 2009, Nature Genetics.

Multiple newly identified loci associated with prostate cancer susceptibility

Ali Amin Al Olama, D. English, J. Morrison, 2008, Nature Genetics.

Balancing autonomy and responsibility: the ethics of generating and disclosing genetic information

R. Eeles, A. Ardern-Jones, N. Hallowell, 2003, Journal of medical ethics.

Juggling roles and expectations: dilemmas faced by women talking to relatives about cancer and genetic testing

R. Eeles, A. Ardern-Jones, M. Watson, 2004 .

Communication about genetic testing in families of male BRCA1/2 carriers and non‐carriers: patterns, priorities and problems

R. Eeles, A. Ardern-Jones, N. Hallowell, 2005, Clinical genetics.

Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers

R. Eeles, Z. Kote-Jarai, A. Ardern-Jones, 2005, British Journal of Cancer.

Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer

R. Eeles, A. Ardern-Jones, S. Edwards, 1998, International journal of cancer.

Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study.

D. Easton, R. Eeles, A. Ardern-Jones, 1997, British journal of urology.

The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers—implications for oncogenetics practice

R. Eeles, Z. Kote-Jarai, A. Ardern-Jones, 2010, Journal of Medical Genetics.

Prostate Cancer Interim Results from the IMPACT Study : Evidence for Prostate-specific Antigen Screening in BRCA 2 Mutation Carriers

W. Foulkes, A. Ardern-Jones, E. Page, 2019 .

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

L. Kiemeney, L. Andrews, R. Eeles, 2019, European urology.

of generating and disclosing genetic information Balancing autonomy and responsibility : the ethics

A. Ardern-Jones, N. Hallowell, C. Foster, 2010 .

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

R. Eeles, A. Ardern-Jones, M. Gore, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests

R. Eeles, A. Ardern-Jones, P. Pharoah, 2011, Hereditary cancer in clinical practice.

Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer

R. Eeles, Z. Kote-Jarai, A. Ardern-Jones, 2002, Prostate Cancer and Prostatic Diseases.

BRCA1/2 predictive testing: a study of uptake in two centres

R. Eeles, A. Ardern-Jones, D. Craufurd, 2004, European Journal of Human Genetics.

No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.

R. Eeles, A. Ardern-Jones, S. Edwards, 1997, British Journal of Cancer.

Apoptosis, ageing and cancer susceptibility

R. Eeles, A. Ardern-Jones, D. Easton, 2003, British Journal of Cancer.

Developments in Clinical Practice: Follow up Clinic for BRCA Mutation Carriers: a Case Study Highlighting the "Virtual Clinic"

R. Eeles, A. Ardern-Jones, A. Ardern-jones, 2004, Hereditary cancer in clinical practice.

ATM polymorphisms as risk factors for prostate cancer development

R. Eeles, T. Dörk, A. Ardern-Jones, 2004, British Journal of Cancer.

Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer.

R. Eeles, Z. Kote-Jarai, A. Ardern-Jones, 2001, Pharmacogenetics.